Toufic Abdo, MD
Endocrinology, Diabetes & Metabolism · Champaign, ILNPI 1962497032
Payments from drug & device makers
Across 16 payments — averaging $255.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$4K
- BETA Bionics, Inc.$58
- Medtronic$46
- Insulet Corporation$34
- Abbott$28
- Amgen$27
- plus $39 from 2 others
What the payments were for
- Consulting fees$2,25055%
- Travel & lodging$1,29732%
- Food & beverage$54313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 6 | $3,858 |
| BETA Bionics, Inc. | 2 | $58 |
| Medtronic | 2 | $46 |
| Insulet Corporation | 1 | $34 |
| Abbott | 2 | $28 |
| Amgen | 1 | $27 |
| Sequel Med Tech, LLC | 1 | $21 |
| Dexcom, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$3,738
How this compares
$4,090 in reported general payments places this provider in the 70th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 351 | $285,065 |
| OzempicSemaglutide | 174 | $183,071 |
| MounjaroTirzepatide | 89 | $101,680 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 72 | $68,404 |
| TrulicityDulaglutide | 53 | $57,804 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 92 | $45,535 |
| Novolog FlexpenInsulin Aspart | 123 | $41,182 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $31,285 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $31,249 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 226 | $31,047 |
| Humalog Kwikpen U-100Insulin Lispro | 99 | $30,730 |
| JanuviaSitagliptin Phosphate | 42 | $30,583 |
| FarxigaDapagliflozin Propanediol | 38 | $20,398 |
| TradjentaLinagliptin | 27 | $18,396 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $13,940 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Champaign
- Liana BillingsSkokie$3.4M
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Hiralal MaheshwariMcHenry$642K
- Wenyu HuangChicago$639K
- Babak PazookiJoliet$582K
- Silvana PannainChicago$575K
- Ammar BayrakdarEvergreen Park$517K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.